Recombinant Human TROP-2 / TACSTD2 Protein, Fc Tag, 2x 100µg

Background
TROP-2 is a single-copy gene in human cells, and encodes a type-1 transmembrane glycoprotein which is over-expressed in various malignancies, also referred to as tumor associated calcium signal transducer 2 (TACSTD2), GA733-1 or M1S1. TROP-2 is related to epithelial cell adhesion molecule (EpCAM), also called TROP-1, gp40, and KSA. Trop-1 and Trop-2 are homologous to serum IGF-II-binding proteins and appear as signal transducers. Thus, they likely represent novel cell-surface receptors and may play a role in regulating the growth of carcinoma cells.

Source
Recombinant Human TROP-2, Fc Tag (TR2-H5253) is expressed from human 293 cells (HEK293). It contains AA Gln 31 - Thr 274 (Accession # P09758-1).
Predicted N-terminus: Gln 31

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 54.3 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis"
Kathpalia, Sharma, Kaur
Ann Pharmacother (2023)
(2) "Future potential targets of antibody-drug conjugates in breast cancer"
Corti, Boscolo Bielo, Schianca et al
Breast (2023) 69, 312-322
(3) "Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer"
Belluomini, Avancini, Sposito et al
Expert Opin Biol Ther (2023)
Showing 1-3 of 238 papers.